Pioglitazone on Pancreatic Steatosis and Bone Health

The University of Texas System (UT)

Status: Completed

Conditions: Obesity; Type 2 Diabetes

Treatments: Drug: placebo; Drug: pioglitazone

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00855010

1K23RRO24470-01

112008-047

Details and patient eligibility

About

Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.

Enrollment: 42 patients

Sex: All

Ages: 21 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Fat level in the pancreas above 4% (measurement done by us with an MRI)
• English speaker
• over 21 years old

Exclusion criteria

• contraindication to MRI
• anemia
• pregnancy or desire to conceive
• use of unapproved medications
• prior pancreatic disease
• use of more then 2 alcoholic drinks every day

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

42 participants in 2 patient groups, including a placebo group

pioglitazone

Experimental group

Description:

pioglitazone tablet 45 mg once daily

Treatment:

Drug: pioglitazone

placebo pill

Placebo Comparator group

Description:

placebo pill once daily (look-alike pill which contains no active ingredients)

Treatment:

Drug: placebo